Dual-Phase Dual-Energy CT in Patients Treated with Erlotinib for Advanced Non-Small Cell Lung Cancer: Possible Benefits of Iodine Quantification in Response Assessment
- 12 November 2015
- journal article
- Published by Springer Nature in European Radiology
- Vol. 26 (8) , 2828-2836
Abstract
To investigate the relationship of dual-phase dual-energy CT (DE-CT) and tumour size in the evaluation of the response to anti-EGFR therapy in patients with advanced non-small cell lung cancer (NSCLC). Dual-phase DE-CT was performed in 31 patients with NSCLC before the onset of anti-EGFR (erlotinib) therapy and as follow-up (mean 8 weeks). Iodine uptake (IU; mg/mL) was quantified using prototype software in arterial and venous phases; arterial enhancement fraction (AEF) was calculated. The change of IU before and after therapy onset was compared with anatomical evaluation in maximal transverse diameter and volume (responders vs. non-responders). A significant decrease of IU in venous phase was proved in responders according to all anatomical parameters (p=0.002–0.016). In groups of non-responders, a significant change of IU was not proved with variable trends of development. The most significant change was observed using the anatomical parameter of volume (cut-off 73 %). A significant difference of percentage change in AEF was proved between responding and non-responders (p=0.019–0.043). Dual-phase DE-CT with iodine uptake quantification is a feasible method with potential benefit in advanced assessment of anti-EGFR therapy response. We demonstrated a decrease in vascularization in the responding primary tumours and non-significant variable development of vascularization in non-responding tumours. • Dual-phase DE-CT is feasible for vascularization assessment of NSCLC with anti-EGFR therapy. • There was a significant decrease of iodine uptake in responding tumours. • There was a non-significant and variable development in non-responding tumours. • There was significant difference of AEF percentage change between responders and non-responders.Keywords
This publication has 30 references indexed in Scilit:
- Histogram Analysis of Iodine Maps from Dual Energy Computed Tomography for Monitoring Targeted Therapy of Melanoma PatientsFuture Oncology, 2015
- Third- and Further-Line Therapy in Advanced Non-Small-Cell Lung Cancer Patients: an OverviewFuture Oncology, 2014
- Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-LineFrontiers in Oncology, 2014
- State of the Art: Response Assessment in Lung Cancer in the Era of Genomic MedicineRadiology, 2014
- Recent developments of dual-energy CT in oncologyEuropean Radiology, 2014
- Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinibCancer Chemotherapy and Pharmacology, 2013
- Comparison of dual-energy CT-derived iodine content and iodine overlay of normal, inflammatory and metastatic squamous cell carcinoma cervical lymph nodesEuropean Radiology, 2013
- Virtual non-contrast in second-generation, dual-energy computed tomography: Reliability of attenuation valuesEuropean Journal of Radiology, 2012
- Non–Small Cell Lung Cancer: Prospective Comparison of Integrated FDG PET/CT and CT Alone for Preoperative StagingRadiology, 2005
- Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial ct scan-based studyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2001